Traditionally, the cost of conducting cancer clinical trials has been supported by a combination of research sponsors, institutions, and third-party payers. However, health insurers and other payers are increasingly reluctant to reimburse for direct patient care provided as part of a clinical trial. These policies--driven in part by a perception that patients enrolled in trials incur substantial additional costs--might impede efforts to enroll patients in clinical trials. Yet there is little evidence regarding the costs of treating patients in clinical trials.
Language
English
Pages
48
Format
Kindle Edition
Publisher
Rand Publishing
Release
August 08, 2000
The Cost of Cancer Treatment Study's Design and Methods (2000)
Traditionally, the cost of conducting cancer clinical trials has been supported by a combination of research sponsors, institutions, and third-party payers. However, health insurers and other payers are increasingly reluctant to reimburse for direct patient care provided as part of a clinical trial. These policies--driven in part by a perception that patients enrolled in trials incur substantial additional costs--might impede efforts to enroll patients in clinical trials. Yet there is little evidence regarding the costs of treating patients in clinical trials.